Project Grant R21DA065898
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $220K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded a cooperative agreement totaling $7.587 million to the University of Pittsburgh on September 19, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research to determine the evolution of whole-person pain characteristics in chronic low back pain (CLBP) individuals and to validate, refine, and augment CLBP models by integrating longitudinal data, chronic overlapping pain conditions (COPCs),...
- The National Institute on Drug Abuse awarded The Regents of the University of California, San Francisco $200,880 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the spatiotemporal dynamics of G protein signaling by opioid receptors. The research investigates how mu-opioid receptors trigger cellular signaling pathways across multiple subcellular compartments, particularly endosomes, to advance understanding of opioid function relevant to...
- The National Institute of Neurological Disorders and Stroke awarded The Regents of the University of California, San Francisco $164,000 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds research into the role of T cell receptor alpha (TRAC) signaling in regulatory T cells' pain-suppressive function. The project investigates how TRAC-mediated signaling regulates neuropathic pain and aims to identify new therapeutic targets and biomarkers for...
- The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health under the Department of Health and Human Services, awarded the University of Maryland, Baltimore $4.929 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a multi-omic, psychosocial, and environmental model of individual differences in pain and placebo responses. The project investigates chronic pain conditions, particularly...
- The National Institute of Neurological Disorders and Stroke awarded The Ohio State University $10.115 million on September 12, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a prospective observational study modeling diverse experiences and longitudinal trajectories of acute pain in emergency department settings. The study—titled MODEL-PAIN (MOdeling Diverse Experiences and Longitudinal trajectories of pain)—will enroll 2,400 emergency department patients and...
- The National Institutes of Health Office of the Director awarded The Regents of the University of California, San Francisco $779,000 on September 4, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop engineered T cells as programmable therapeutic delivery vehicles for chronic pain treatment. The research integrates immunology, neuroscience, and synthetic biology to reprogram regulatory T cells with synthetic receptors designed to home to dorsal root ganglia and detect...
- The National Institute on Drug Abuse awarded The Trustees of the University of Pennsylvania $100,228 on January 14, 2027, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct data science-driven analysis of opioid use trajectories among opioid-naive individuals following arthroplasty. The recipient will develop a prediction model to identify patients at risk for new persistent opioid use (NPOU)—prolonged opioid exposure beyond the typical three-month post-operative...
- The National Institute on Drug Abuse awarded Duke University $722,472 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized, double-blinded study examining very low nicotine content cigarettes as a smoking cessation intervention for individuals with chronic back pain. The research addresses high comorbidity between tobacco smoking and chronic pain, where nicotine's mild anti-nociceptive effects create powerful negative reinforcement and...
- The National Institute on Drug Abuse awarded the University of Utah $162,200 on October 10, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to characterize pain embodiment and its relationship to opioid misuse risk in chronic pain using neuroimaging. The award funds a five-year research project through September 30, 2030, performed in Salt Lake City, Utah. The research will employ resting-state functional magnetic resonance imaging to study pain embodiment—the tendency...
- The National Institute of Neurological Disorders and Stroke awarded the Regents of the University of Michigan a $6.827 million cooperative agreement on September 19, 2025, to conduct a Sequential Multiple Assignment Randomized Trial (SMART) evaluating personalized treatment algorithms for chronic low back pain across pharmacological, physical therapy, cognitive-behavioral, and mobile health self-management interventions. The University of Michigan's Back Pain Consortium Mechanistic Research...